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Abstract
Background: Genomic structural variants (SVs) can affect many genes and regulatory elements. Therefore, the
molecular mechanisms driving the phenotypes of patients carrying de novo SVs are frequently unknown.
Methods: We applied a combination of systematic experimental and bioinformatic methods to improve the
molecular diagnosis of 39 patients with multiple congenital abnormalities and/or intellectual disability harboring
apparent de novo SVs, most with an inconclusive diagnosis after regular genetic testing.
Results: In 7 of these cases (18%), whole-genome sequencing analysis revealed disease-relevant complexities of the
SVs missed in routine microarray-based analyses. We developed a computational tool to predict the effects on
genes directly affected by SVs and on genes indirectly affected likely due to the changes in chromatin organization
and impact on regulatory mechanisms. By combining these functional predictions with extensive phenotype
information, candidate driver genes were identified in 16/39 (41%) patients. In 8 cases, evidence was found for the
involvement of multiple candidate drivers contributing to different parts of the phenotypes. Subsequently, we
applied this computational method to two cohorts containing a total of 379 patients with previously detected and
classified de novo SVs and identified candidate driver genes in 189 cases (50%), including 40 cases whose SVs were
previously not classified as pathogenic. Pathogenic position effects were predicted in 28% of all studied cases with
balanced SVs and in 11% of the cases with copy number variants.
Conclusions: These results demonstrate an integrated computational and experimental approach to predict driver
genes based on analyses of WGS data with phenotype association and chromatin organization datasets. These
analyses nominate new pathogenic loci and have strong potential to improve the molecular diagnosis of patients
with de novo SVs.
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Background
De novo constitutional structural variations (SVs) in-
cluding deletions, duplications, inversions, insertions,
and translocations are important causes of (neuro-)de-
velopmental disorders such as intellectual disability and
autism spectrum disorder (ASD) [1, 2]. Clinical genetic
centers routinely use microarrays, as well as karyotyping
in some cases, to detect SVs at kilo- to megabase reso-
lution [3]. The interpretation of the pathogenicity of an
SV mainly relies on finding overlap with SVs in other
patients with similar phenotypes [4, 5]. SVs can affect
large genomic regions which can contain many genes
and non-coding regulatory elements [1]. This makes it
challenging to determine which and how specific af-
fected gene(s) and regulatory elements contributed to
the phenotype of a patient. Therefore, the causative
genes driving the phenotype are frequently unknown for
patients with de novo SVs which can hamper conclusive
genetic diagnosis.
SVs can have a direct effect on the expression and
functioning of genes by altering their copy number or by
truncating their coding sequences [1]. In addition, SVs
can indirectly influence the expression of adjacent genes
by disrupting the interactions with their regulatory ele-
ments [6]. New developments in chromatin conform-
ation capture (3C)-based technologies such as Hi-C have
provided the means to study these indirect, position
effects [7]. Most of the genomic interactions (loops) be-
tween genes and enhancers occur within megabase-sized
topologically associating domains (TADs). These do-
mains are separated from each other by boundary
elements characterized by CTCF-binding, which limit
the interactions between genes and enhancers that are
not located within the same TAD [8, 9]. For several loci,
such as the EPHA4 [10], SOX9 [11], IHH [12], and Pitx
[13] loci, it has been demonstrated that disruption of
TAD boundaries by SVs can cause rewiring of genomic
interactions between genes and enhancers, which can
lead to altered gene expression during embryonic devel-
opment and ultimately in disease phenotypes [14].
Although the organization of TADs appears to be stable
across cell types, sub-TAD genomic interactions be-
tween genes and regulatory elements have been shown
to be relatively dynamic and cell type-specific [15]. Dis-
ruptions of genomic interactions are therefore optimally
studied in disease-relevant cell types, which may be ob-
tained from mouse models or from patient-derived in-
duced pluripotent stem cells. However, it is not feasible
to study each individual locus or patient with such elab-
orate approaches, and disease-relevant tissues derived
from patients are usually not available. Therefore, it is
not yet precisely known how frequently position effects
contribute to the phenotypes of patients with develop-
mental disorders.
A few computational tools such as SVScore and the
Ensembl Variant Effect Predictor have been developed
to predict the pathogenicity of SVs, but these mainly
predict the potential direct impact of SVs on genes and
do not take the specific phenotype of the patient into
account [16, 17]. It has been shown that the use of com-
putational methods based on combining phenotypic in-
formation from the Human Phenotype Ontology (HPO)
database (phenomatching) with previously published
chromatin interaction datasets can improve the inter-
pretation of the molecular consequences of de novo SVs
[18–20]. These approaches have largely been based on
data derived from a small set of cell types and tech-
niques. Here, we further expand these in silico ap-
proaches by integrating detailed phenotype information
with genome-wide chromatin conformation datasets of
many different cell types. By combining this method
with whole-genome and transcriptome sequencing, we
predicted which genes are affected by the SVs and which
of these genes have likely been involved in the develop-
ment of the disease phenotype (e.g., candidate driver
genes). Accurate characterization of the effects of SVs on
genes can be beneficial for the prediction of potential clin-
ical relevance of the SVs. Detailed interpretation of the
molecular effects of the SVs helped to identify candidate
driver genes in 16 out of 39 patients who had an inconclu-
sive diagnosis after conventional genetic testing. By apply-
ing the computational method on larger cohorts of
patients with de novo SVs, we estimated the contribution
of position effects for both balanced and unbalanced SVs.
Methods
Patient selection and phenotyping
A total of 39 individuals with de novo germline SVs and
an inconclusive diagnosis were included in this study.
Individuals P1 to P21 and their biological parents were
included at the University Medical Center Utrecht (the
Netherlands) under study ID NL55260.041.15 15-736/M.
Individual P22, previously described by Redin et al. as
UTR22 [21], and her parents were included at the San
Luigi University Hospital (Italy). For individuals P23 to
P39, lymphoblastoid cell lines (LCL) were previously de-
rived as part of the Developmental Genome Anatomy
Project (DGAP) of the Brigham and Women’s Hospital
and Massachusetts General Hospital, Boston, MA, USA
[21]. Written informed consent was obtained for all
included individuals and parents, and the studies were
approved by the respective institutional review boards.
DNA and RNA extraction
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from whole blood samples of individuals P1 to P22
and their biological parents using a Ficoll-Paque Plus
gradient (GE Healthcare Life Sciences) in SepMate tubes
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(STEMCELL Technologies) according to the manufac-
turer’s protocols. LCL derived from individuals P23 to
P39 were expanded in RPMI 1640 medium supple-
mented with GlutaMAX (Thermo Fisher Scientific), 10%
fetal bovine serum, 1% penicillin, and 1% streptomycin
at 37 °C. LCL cultures of each individual were split into
three flasks and cultured separately for at least 1 week to
obtain technical replicate samples for RNA isolation.
Genomic DNA was isolated from the PBMCs or LCL
using the QIASymphony DNA kit (Qiagen). Total RNA
was isolated using the QIAsymphony RNA Kit (Qiagen),
and RNA quality (RIN > 8) was determined using the
Agilent RNA 6000 Nano Kit.
Whole-genome sequencing
Purified DNA was sheared into fragments of 400–500 bp
using a Covaris sonicator. WGS libraries were prepared
using the TruSeq DNA Nano Library Prep Kit (Illumina).
WGS libraries were sequenced on an Illumina Hiseq X in-
strument generating 2 × 150 bp paired-end reads to a
mean coverage depth of at least × 30. The WGS data was
processed using an in-house Illumina analysis pipeline
(https://github.com/UMCUGenetics/IAP). Briefly, reads
were mapped to the CRCh37/hg19 human reference gen-
ome using BWA-0.7.5a using “BWA-MEM -t 12 -c 100
-M -R” [22]. GATK IndelRealigner [23] was used to re-
align the reads. Duplicated reads were removed using
Sambamba markdup [24].
Structural variant calling and filtering
Raw SV candidates were called with Manta v0.29.5 using
standard settings [25] and Delly v0.7.2 [26] using the
following settings: “-q 1 -s 9 -m 13 -u 5.” Only Manta
calls overlapping with breakpoint junctions called by
Delly (± 100 bp) were selected. Rare SVs were selected
by filtering against SV calls of 1000 Genomes [27] and
against an in-house database containing raw Manta
SV calls of ~ 120 samples (https://github.com/UMCU
Genetics/vcf-explorer). De novo SVs were identified in
individuals P1 to P22 by filtering the SVs of the chil-
dren against the Manta calls (± 100 bp) of the father
and the mother. Filtered SV calls were manually
inspected in the Integrative Genome Viewer (IGV).
The conformations of the complex derivative chromo-
somes were manually reconstructed based on genomic
orientations of the filtered SV calls. De novo break-
point junctions of individuals P1 to P21 were validated
by PCR using AmpliTaq gold (Thermo Scientific)
under standard cycling conditions and by Sanger se-
quencing. Primers were designed using Primer3 soft-
ware (Additional file 1: Table S1). Breakpoint junction
coordinates for individuals P22 to P39 were previously
validated by PCR [21, 28].
Single nucleotide variant filtering
Single nucleotide variants and indels were called using
GATK HaplotypeCaller. For individuals P1 to P21
(whose parents were also sequenced), reads overlapping
exons were selected and the Bench NGS Lab platform
(Agilent-Cartagenia) was used to detect possible patho-
genic de novo or recessive variants in the exome. The
identified single nucleotide variants were classified accord-
ing to the American College of Medical Genetics and
Genomics (ACMG) criteria. De novo variants were only
analyzed if they affect the protein structure of the genes
that are intolerant to missense and loss-of-function vari-
ants. Only putative protein-changing homozygous and
compound heterozygous variants with an allele frequency
of < 0.5% in ExAC [29] were reported.
RNA sequencing and analysis
RNA-seq libraries were prepared using TruSeq Stranded
Total RNA Library Prep Kit (Illumina) according to the
manufacturer’s protocol. RNA-seq libraries were pooled
and sequenced on a NextSeq500 (Illumina) in 2 × 75 bp
paired-end mode. Processing of RNA sequencing data
was performed using a custom in-house pipeline
(https://github.com/UMCUGenetics/RNASeq). Briefly,
reads were aligned to the CRCh37/hg19 human reference
genome using STAR 2.4.2a [30]. The number of reads map-
ping to genes were counted using HTSeq-count 0.6.1 [31].
Genes overlapping with SV breakpoints (e.g., truncated
genes) were also analyzed separately by counting the num-
ber of reads mapping to exons per truncated gene fragment
(up- and downstream of the breakpoint junction). RNA-seq
data obtained from PBMCs (individuals P1 to P22) and
LCL (individuals P23 to P39) were processed as separate
datasets. The R-package DESeq2 was used to normalize
raw read counts and to perform differential gene expression
analysis for both datasets separately [32]. Genes with more
than 0.5 reads per kilobase per million (RPKM) mapped
reads were considered to be expressed.
Gene annotation
Gene information (including genomic positions, Ensembl
IDs, HGNC symbols, and Refseq IDs) was obtained from
Ensembl (GRCh37) using the R-package biomaRt (v2.38)
[33]. Genes containing a RefSeq mRNA ID and a HGNC
symbol were considered as protein-coding genes. Gen-
omic coordinates for the longest transcript were used if
genes contained multiple RefSeq mRNA IDs. The list of
19,300 protein-coding genes was further annotated with
(1) pLI, (2) RVIS, (3) haploinsufficiency (HI) and triplo-
sensitivity scores, (4) OMIM identifiers, and (5) DDG2P
information for each gene (see Additional file 1: Table S2
for data sources). These five categories were used to calcu-
late a “disease association score” for each gene, which in-
dicates if the gene has been associated with developmental
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disorders in general. Each gene was assigned one point
per category if it met the following criteria (Table 1): (1) a
pLI score of more than 0.9, (2) a RVIS score of less than
10, (3) a haploinsufficiency score of less than 10 or a
ClinGen haploinsufficiency or triplosensitivity score be-
tween 1 and 3, (4) presence in the DDG2P database, and
(5) presence in the OMIM database. Therefore, the dis-
ease association score ranges from 0 to 5, and a higher
score indicates that the gene is associated with develop-
mental disorders in multiple databases. Modes of inherit-
ance for each gene (e.g., autosomal dominant, autosomal
recessive, or X-linked) were retrieved from the HPO and
DDG2P databases.
Computational prediction of the effects of SVs on genes
For each patient, the protein-coding genes located at or
adjacent (< 2Mb) to the SVs were selected. The HPO
terms linked to these genes in the HPO database were
matched to each individual HPO term assigned to the
patient and to the combination of the patient’s HPO
terms. For each gene, the number of phenomatch scores
higher than 1 (low phenomatches) and higher than 5
(high phenomatches) with individual patient HPO terms
was calculated. The strength of the association (none,
weak, medium, or strong) of each selected gene with the
phenotype of the patient was determined based on the
total phenomatch score, the number of low and high
phenomatches, the mode of inheritance, and the disease
association score (Table 1, Additional file 2: S1a).
Subsequently, potential direct and indirect effects of
the SVs (none, weak, or strong) on the genes were pre-
dicted (Table 1, Additional file 2: Figure S1a). The pre-
diction analyses were based on chromatin organization
and epigenetic datasets of many different cell types ob-
tained from previous studies (see Additional file 1: Table
S2 for data sources).
First, we determined which TADs of 20 different cell
types overlapped with the de novo SVs and which genes
were located within these disrupted TADs [34–36]
(Additional file 2: Figure S1b). To determine if the dis-
rupted portions of the TADs contained regulatory ele-
ments that may be relevant for the genes located in the
affected TADs, we selected the 3 cell types in which the
gene is highly expressed based on RNA-seq data from the
Encode/Roadmap projects [37] reanalyzed by Schmitt
et al. [34] (Additional file 2: Figure S1C). The number of
active enhancers (determined by chromHMM analysis of
Encode/Roadmap ChIP-seq data [37]) in the TADs up-
and downstream of the breakpoint junction in the 3 se-
lected cell types was counted (Additional file 2: Figure
SS1D). Virtual 4C was performed by selecting the rows of
the normalized Hi-C matrices containing the transcription
start site coordinates of the genes. The v4C profiles were
overlapped with the breakpoint junctions to determine the
portion of interrupted Hi-C interactions of the gene
Table 1 Cutoffs used to classify affected genes as T1, T2, or T3 candidate driver genes
1. Phenotype association
Weak Medium Strong
Disease association score (0–5) pLI > 0.9
RVIS < 10
HI < 10
DDG2P
OMIM
> 0 > 0 > 2
Total phenomatch score > 0 > 4 > 10
Phenomatches (% of HPO terms with phenomatch score > 5) > 0 > 10% > 25%
Mode of inheritance AD/XD/XR+XY AD/XD/XR+XY
2. Effect of SV on gene
Weak Strong
Gene location Adjacent Dup Adjacent DEL/TRUNC
Support score (0–6) TAD disrupted
V4C disrupted
PCHiC disrupted
DHS disrupted
RNA expression
> 1 NA > 3 NA
3. Driver classification
Classification T3 T2 T1
Phenotype association + effect of SV on gene Weak + weak Strong + weak Medium + strong Strong + strong
pLI probability of being loss-of-function intolerant, RVIS Residual Variation Intolerance Score, HI haploinsufficiency, DDG2P Developmental Disorders Genotype-
Phenotype Database, OMIM Online Mendelian Inheritance in Man, AD autosomal dominant, XD X-linked dominant, XR X-linked recessive, XY male, TAD
topologically associating domain, V4C virtual 4C, PCHiC promoter capture Hi-C, DHS DNase hypersensitivity site
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(Additional file 2: Figure S1e). In addition, promoter cap-
ture Hi-C data of 22 tissue types [38–41] and DNAse
hypersensitivity site (DHS) connections [42] were over-
lapped with the SV breakpoints to predict disruption of
long-range interactions over the breakpoint junctions
(Additional file 2: Figure S1f). Genes with at least a weak
phenotype association and a weak SV effect are considered
as T3 candidate genes. Genes were classified as T1 candi-
date drivers if they have a strong association with the
phenotype and are strongly affected by the SV. Genes clas-
sified as T2 candidate driver can have a weak/medium
phenotype association combined with a strong SV effect
or they can have a medium/strong phenotype association
with a weak SV effect (Fig. 2a, Table 1).
SV and phenotype information large patient cohorts
Breakpoint junction information and HPO terms for 228
individuals (excluding the individuals already included in
this study for WGS and RNA-seq analysis) with mostly bal-
anced SVs were obtained from Redin et al. [21]. Phenotype
and genomic information for 154 patients with de novo
copy number variants ascertained by clinical genomic ar-
rays were obtained from an in-house patient database from
the University Medical Center Utrecht (the Netherlands).
Results
WGS reveals hidden complexity of de novo SVs
We aimed to improve the genetic diagnosis of 39 indi-
viduals with multiple congenital abnormalities and/or in-
tellectual disability (MCA/ID) who had an inconclusive
diagnosis after regular genetic testing or who have
complex genomic rearrangements. The phenotypes of
the individuals were systematically described by Human
Phenotype Ontology (HPO) terms [45–47]. The included
individuals displayed a wide range of phenotypic fea-
tures, and most individuals (82%) presented neurological
abnormalities including intellectual disability (Fig. 1a,
Additional file 1: Table S3) [21]. The parents of each of
the patients were healthy, suggesting a de novo or reces-
sive origin of the disease phenotypes. All individuals car-
ried de novo SVs which were previously detected by
ArrayCGH, SNP arrays, karyotyping, long-insert whole-
genome sequencing, mate-pair sequencing, or targeted
sequencing (Additional file 2: Figure S2a). First, we per-
formed whole-genome sequencing (WGS) for all individ-
uals in the cohort to screen for potential pathogenic
genetic variants that were not detected by the previously
performed genetic tests. No known pathogenic single
nucleotide variants (SNVs) were detected in the individ-
uals analyzed by patient-parents trio-based WGS (indi-
viduals P1 to P20), except for 1 pathogenic SNV that is
associated with 1 component (hemophilia) of the comor-
bid phenotypic presentations of individual P1. A total of
46 unbalanced and 219 balanced de novo SVs were
identified in the genomes of the individuals (Fig. 1b,
Additional file 2: Figure S2b, Additional file 1: Table
S1). The detected SVs ranged from simple SVs to very
complex genomic rearrangements that ranged from 4
to 40 breakpoint junctions per individual. Importantly,
WGS confirmed all previously detected de novo SVs
and revealed additional complexity of the SVs in 7
(39%) of the 18 cases who were not studied by WGS-
based techniques before (Fig. 1c, d; Additional file 1:
Table S1). In half of the cases with previously identified
de novo copy number gains (4/8), the gains were not
arranged in a tandem orientation, but instead, they
were inserted in another genomic region, which can
have far-reaching consequences for accurate interpretation
of the pathogenetic mechanisms in these individuals
(Fig. 1d) [48–50]. This suggests that the complexity of copy
number gains in particular is frequently underestimated by
microarray analysis. For example, in one case (P11), a previ-
ously detected 170-kb copy number gain from chromo-
some 9 was actually inserted into chromosome X, 82 kb
upstream of the SOX3 gene (Fig. 1d, Additional file 2:
Figure S3). This inserted fragment contains a super-
enhancer region that is active in craniofacial development
[51] (Additional file 2: Figure S3). The insertion of the
super-enhancer may have disturbed the regulation of SOX3
expression during palate development, which may repre-
sent a causal variant associated with the orofacial clefting in
this individual [52–56]. The detection of these additional
complexities in these seven patients exemplifies the added
value that WGS analyses can have for cases that remain un-
resolved after standard array diagnostics [50].
In silico phenomatching approach links directly affected
genes to phenotypes
Subsequently, we determined if the phenotypes of the pa-
tients could be explained by direct effects of the de novo
SVs, most of which were previously classified as a variant
of unknown significance (VUS), on genes. In total, 332
genes are directly affected (deleted, duplicated, or trun-
cated) by the de novo SVs in the cohort (Additional file 2:
Figure S2c). The phenomatch tool was used to match the
HPO terms associated with these genes with the HPO
terms used to describe the phenotypes of the individuals
[18, 19]. Genes were considered as candidate driver genes
based on the height of their phenomatch score, the num-
ber of phenomatches between the HPO terms of the gene
and the patient, recessive or dominant mode of inherit-
ance, dosage sensitivity scores [57], loss-of-function con-
straint score (pLI) [29], Residual Variation Intolerance
Score (RVIS) [58], and the presence in OMIM and/or
DDG2P [59] databases (Table 1). Directly affected genes
strongly or moderately associated with the phenotype are
classified as tier 1 (T1) and tier 2 (T2) candidate driver
genes, respectively (Fig. 2a, Table 1). Genes with limited
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evidence for contribution to the phenotype are reported
as tier 3 (T3) genes. In the cohort of 39 patients, this ap-
proach prioritized 2 and 13 of the 332 directly affected
genes as T1 and T2 candidate drivers, respectively
(Fig. 2b). In 3 cases, the HPO terms of the identified T1/
T2 candidate driver genes could be matched to more than
Fig. 1 Characterization of de novo SVs in a cohort of individuals with neurodevelopmental disorders. a Frequencies of clinical phenotypic
categories described for the 39 included individuals based on the categories defined by HPO. Nervous system abnormalities are divided into 4
subcategories. b Number of de novo breakpoint junctions per SV type identified by WGS of 39 included patients. Most detected de novo SVs are
part of complex genomic rearrangements, which are defined by the involvement of more than 3 breakpoint junctions (SVs with 1 or 2
breakpoint junctions are considered simple rearrangements). c Number of cases in which WGS analysis identified new, additional, or similar SVs
compared to microarray-based copy number profiling. d Schematic representation of additional genomic rearrangements that were observed by
WGS in 5 individuals. For each patient, the top panel shows the de novo SVs identified by arrays or karyotyping and bottom panel shows the
structures of the SVs detected by WGS. The WGS data of individual P8 revealed complex chromoanasynthesis rearrangements involving multiple
duplications and an insertion of a fragment from chr14 into chr3. Individual P11 has an insertion of a fragment of chr9 into chrX that was
detected as a copy number gain by array-based analysis (Additional file 2: Figure S2). The detected copy number gains in individuals P12 and P21
show an interspersed orientation instead of a tandem orientation. The translocation in patient P20 appeared to be more complex than previously
anticipated based on karyotyping results, showing 11 breakpoint junctions on 3 chromosomes
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75% of the HPO terms assigned to the patients, indicating
that the effects of the SVs on these genes can explain most
of the phenotypes of these patients (Additional file 1:
Table S4). In 6 other cases, directly affected T1/T2 can-
didate drivers were identified that were only associated
with a part of the patient’s phenotypes (Additional file 1:
Table S4).
Subsequently, we performed RNA sequencing on pri-
mary blood cells or lymphoblastoid cell lines derived
from all 39 individuals to determine the impact of de
novo SVs on RNA expression of candidate driver genes.
RNA sequencing confirmed that most expressed genes
directly affected by de novo deletions show a reduced
RNA expression (97 of 107 genes with a median reduc-
tion of 0.46-fold compared to non-affected individuals)
(Fig. 2d). Although duplicated genes show a median of
1.44-fold increase in expression, only 14 of 43 (~ 30%) of
them are significantly overexpressed compared to the
expression levels in non-affected individuals. In total,
87 genes are truncated by SVs and 4 of these are classi-
fied as T1/T2 candidate drivers. The genomic rear-
rangements lead to 12 possible fusions of truncated
genes, and RNA-seq showed an increased expression
for 2 gene fragments due to the formation of a fusion
gene (Additional file 2: Figure S4, Additional file 1:
Table S5). None of the genes involved in the formation
of fusion genes were associated with the phenotypes of
the patients, although we cannot exclude an unknown
pathogenic effect of the newly identified fusion genes.
We could detect expression for 3 deleted and 2 dupli-
cated T1/T2 candidate drivers, and these were differen-
tially expressed when compared to controls. The RNA
Fig. 2 Prediction of candidate driver genes directly and indirectly affected by the SVs. a Schematic overview of the computational workflow
developed to detect candidate driver genes. Classification of genes at (direct) or surrounding (indirect) the de novo SVs is based on the
association of the gene with the phenotype and the predicted direct or indirect effect on the gene (Table 1). b Total number of identified tier 1,
2, and 3 candidate driver genes predicted to be directly or indirectly affected by an SV. c Genome browser overview showing the predicted
disruption of regulatory landscape of the HOXD locus in individual P22. A 107-kb fragment (red shading) upstream of the HOXD locus (green
shading) is translocated to a different chromosome, and a 106-kb fragment (yellow shading) is inverted. The SVs affect the TAD centromeric of
the HOXD locus which is involved in the regulation of gene expression in developing digits. The translocated and inverted fragments contain
multiple mouse [43] and human (day E41) [44] embryonic limb enhancers, including the global control region (GCR). Disruptions of these
developmental enhancers likely contributed to the limb phenotype of the patient. The virtual V4C track shows the Hi-C interactions per 10 kb bin
in germinal zone (GZ) cells using the HOXD13 gene as viewpoint [35]. The bottom track displays the PCHiC interactions of the HOXD13 gene in
neuroectodermal cells [40]. UCSC Liftover was used to convert mm10 coordinates to hg19. d RNA expression levels of genes at or adjacent to de
novo SVs. Log2 fold RNA expression changes compared to controls (see the “Methods” section) determined by RNA sequencing for expressed
genes (RPKM > 0.5) that are located within 2 Mb of SV breakpoint junctions (FLANK) or that are inverted (INV), duplicated (DUP), deleted (DEL), or
truncated (TRUNC). Differentially expressed genes (p < 0.05, calculated by DESeq2) are displayed in red
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sequencing data suggests that most genes affected by
de novo deletions show reduced RNA expression levels
and limited dosage compensation. However, increased
gene dosage by de novo duplications does not always
lead to increased RNA expression, at least in the blood
cells of patients.
Prediction of position effects of de novo SVs on
neighboring genes
In 28 of the included cases (72%), our prioritization
method did not predict T1/T2 candidate driver genes
that are directly affected by the de novo SVs. Therefore,
we investigated the position effects on the genes
surrounding the de novo SVs to explain the phenotypes
in those cases that were not fully explained by directly
affected candidate driver genes. We extended our candi-
date driver gene prioritization analysis by including all
the protein-coding genes located within 2Mb of the
breakpoint junctions, as most chromatin interactions are
formed between the loci that are less than 2Mb apart
from each other [60]. Of the 2754 genes adjacent to the
SVs, 117 are moderately to strongly associated with the
specific phenotypes of the individuals based on the
phenotype association analysis. However, this association
with the phenotype does not necessarily mean that these
genes located within 2Mb of the breakpoint junctions
are really affected by the SVs and thus contributing to
the phenotype. To determine if the regulation of these
genes was affected, we first evaluated the RNA expres-
sion levels of those genes. Three quarters (81/117) of the
genes linked to the phenotypes were expressed, but only
9 of these showed reduced or increased expression
(Fig. 2d). However, RNA expression in the blood may
not always be a relevant proxy for most neurodevelop-
mental phenotypes [61, 62]. Therefore, we developed an
extensive in silico strategy to predict potential disruption
of the regulatory landscape of the genes surrounding the
SVs (Additional file 2: Figure S1). Because the interactions
between genes and their regulatory elements are cell type-
specific, a large collection of tissue-specific Hi-C, TAD,
promoter capture Hi-C (PCHiC), DNase hypersensitivity
site (DHS), RNA, and ChIP-seq datasets was included
(Additional file 1: Table S2). Several embryonic and neural
cell type (such as fetal brain and neural progenitor cells)
datasets were included that may be especially relevant to
study the neurodevelopmental phenotypes in our cohort.
To predict potential disruption of the regulatory land-
scape of genes, we first selected for each of the assessed
cell types the (1) TADs [34–36], (2) the PCHiC interac-
tions [38–41], and (3) DHS connections [42] overlapping
with the transcription start site of each gene adjacent to
the SVs. We overlapped these gene-specific genome
conformation features with the breakpoint junctions of
the identified SVs to determine the proportion of
disrupted genomic interactions for each gene (the
“Methods” section, Additional file 2: Figure S1). We also
counted the number of enhancers (which are active in
cell types in which the genes show the highest RNA ex-
pression [37]) that are located on disrupted portions of
the TADs. Additionally, we performed virtual 4C (v4C)
for each gene by selecting the rows of the normalized
Hi-C matrices containing the transcription start site co-
ordinates of the genes as viewpoints, because the coordi-
nates of TAD boundaries can be dependent on the
calling method and the resolution of the Hi-C [63–65]
and because a significant portion of genomic interac-
tions crosses TAD boundaries [9]. Integrated scores for
TAD disruption, v4C disruption, potential enhancer loss,
disruption of PCHiC interactions, and DHS connections
were used to calculate a position effect support score for
each gene (Additional file 2: Figure S1). Finally, indir-
ectly affected genes were classified as tier 1, 2, or 3
candidate drivers based on a combination of their as-
sociation with the phenotype and their support score
(Fig. 2a, Table 1).
Of the 117 genes that were associated with the pheno-
types and located within 2Mb of the SVs, 16 genes were
predicted to be affected by the SVs based on the in silico
analysis and therefore classified as T1/T2 candidate
driver gene (Fig. 2b, Additional file 2: Figure S5). The
validity of the approach was supported by the detection
of pathogenic position effects identified in previous stud-
ies. For example, the regulatory landscape of SOX9 was
predicted to be disturbed by a translocation 721 kb up-
stream of the gene in individual P5, whose phenotype is
mainly characterized by acampomelic campomelic dys-
plasia with Pierre-Robin syndrome (PRS) including a
cleft palate (Additional file 2: Figure S6). SVs in this re-
gion have been predicted to disrupt interactions of
SOX9 with several of its enhancers further upstream,
leading to phenotypes similar to the phenotype of indi-
vidual P5 [66, 67]. In individual P39, who has been pre-
viously included in other studies, our method predicted
a disruption of FOXG1 expression regulation due to a
translocation (Additional file 2: Figure S1), further sup-
porting the hypothesis that deregulation of FOXG1
caused the phenotype of this individual [21, 68].
Another example of a predicted position effect is the
disruption of the regulatory landscape of the HOXD
locus in individual P22. This individual has complex
genomic rearrangements consisting of 40 breakpoint
junctions on 4 different chromosomes likely caused by
chromothripsis [28]. One of the inversions and 1 of the
translocations are located in the TAD upstream (centro-
meric) of the HOXD gene cluster (Fig. 2c). This TAD
contains multiple enhancers that regulate the precise ex-
pression patterns of the HOXD genes during the devel-
opment of the digits [43, 69, 70]. Deletions of the gene
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cluster itself, but also deletions upstream of the cluster,
are associated with hand malformations [71–73]. The
translocation in individual P22 disrupts 1 of the main
enhancer regions (the global control region (GCR)),
which may have led to altered regulation of the expres-
sion of HOXD genes, ultimately causing brachydactyly
and clinodactyly in this patient.
Our approach predicted position effects on T1/T2
candidate driver genes in ten included cases (26%) of
which eight cases have balanced or complex SVs. This
suggests that these effects may be especially important
for balanced SVs.
Prediction of driver genes improves molecular diagnosis
By combining both directly and indirectly affected can-
didate drivers per patient, we found possible explana-
tions for the phenotypes of 16/39 (41%) complex and/
or previously unsolved cases (Fig. 3a, Additional file 1:
Table S4). Interestingly, in 8 cases, we found evidence
for multiple candidate drivers that are individually only
associated with part of the phenotype, but together may
largely explain the phenotype (Fig. 3b). For example, we
identified 4 candidate drivers in individual P25, who
has a complex phenotype characterized by developmen-
tal delay, autism, seizures, renal agenesis, cryptorchid-
ism, and an abnormal facial shape (Fig. 3c). This
individual has complex genomic rearrangements
consisting of 6 breakpoint junctions and 2 deletions of
~ 10Mb and ~ 0.6 Mb on 3 different chromosomes
(Fig. 3d). The 6q13q14.1 deletion of ~ 10Mb affects 33
genes including the candidate drivers PHIP and
COL12A1, which have been associated with develop-
mental delay, anxiety, and facial dysmorphisms in other
patients [74, 75]. In addition, 2 genes associated with
other parts of the phenotype were predicted to be af-
fected by position effects (Fig. 3e). One of these genes
is TFAP2A, whose TAD (characterized by a large gene
desert) and long-range interactions overlap with a
translocation breakpoint junction. Rearrangements af-
fecting the genomic interactions between TFAP2A and
enhancers active in neural crest cells located in the
TFAP2A TAD have recently been implicated in
branchio-oculofacial syndrome [76]. The regulation of
BMP2, a gene linked to agenesis of the ribs and cardiac
features, is also predicted to be disturbed by a complex
SV upstream of this gene [77, 78]. Altogether, these
candidate driver genes may have jointly contributed to
the phenotype of this individual (Fig. 3d). This case
illustrates the challenge of identifying the causal genes
driving the phenotypes of patients with structural rear-
rangements and highlights the notion that multiple
genes should be considered for understanding the
underlying molecular processes and explaining the pa-
tient’s phenotype [79].
In silico driver gene prediction in larger patient cohorts
Our candidate driver prioritization approach identified
many candidate drivers in previously unresolved cases,
but these complex cases may not be fully representative
for the general patient population seen in clinical genetic
diagnostics. Therefore, we applied our prediction method
to 2 larger sets of patients with de novo SVs to further as-
sess the validity and value of the approach. We focused on
the genes located at or within 1Mb of the SVs, because
most of the candidate driver genes we identified in our
own patient cohort were located within 1Mb of an SV
breakpoint junction (Fig. 3f). First, we determined the ef-
fects of largely balanced structural variants in 225 previ-
ously described patients with varied congenital anomalies
(Additional file 2: Figure S7a) [21]. In 98 of the 225 (44%)
cases, the detected de novo SVs were previously classified
as pathogenic or likely pathogenic, and in all but 3 of these
diagnosed cases, 1 or more candidate driver genes have
been proposed (Additional file 2: Figure S7b). Our ap-
proach identified 46 T1 and 97 T2 candidate drivers
out of 7406 genes located within 1Mb of the SVs (Add-
itional file 2: Figure S7c,d; Additional file 1: Table S6).
More than half (89/143) of the identified T1/T2 candi-
date drivers were not previously described as driver
genes. In contrast, 22/114 (22%) previously described
pathogenic or likely pathogenic drivers were classified
as T3 candidates, and 38/114 (33%) were not reported
as a driver by our approach (Fig. 4a), mostly because
the phenomatch scores were below the threshold (46%)
or because the genes were not associated with HPO
terms (41%) (Additional file 2: Figure S7e). T1/T2 can-
didate drivers were identified in 101/225 (44%) of the
individuals with mostly balanced SVs, including 31 in-
dividuals with SVs that were previously classified as
VUS (Fig. 4b, Additional file 2: Figure S8). Position ef-
fect on genes moderately to strongly associated with
the phenotypes was predicted in 64 (28%) of the cases
with balanced SVs.
Subsequently, we also assessed the value of our driver
prioritization approach for individuals with unbalanced
copy number variants. We collected genetic and pheno-
typic information of 154 patients with a broad spectrum
of (neuro-)developmental disorders who harbor de novo
copy number variants (< 10Mb) that were identified by
clinical array-based copy number profiling (Add-
itional file 2: Figure S7a,b; Additional file 1: Table S7).
The CNVs in the majority (83%) of these individuals
have been previously classified as pathogenic according
to the clinical genetic diagnostic criteria (Additional file 2:
Figure S7b). These criteria are mostly based on the over-
lap of the CNVs with CNVs of other individuals with
similar phenotypes, and the causative driver genes were
typically not previously specified. Our method identified
T1/T2 candidate driver genes in 88/154 (57%) individuals,
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Fig. 3 (See legend on next page.)
Middelkamp et al. Genome Medicine           (2019) 11:79 Page 10 of 15
including 9/26 individuals with CNVs previously classified
as VUS (Fig. 4a, Additional file 1: Table S6). Interestingly,
support for position effects on candidate drivers was only
found in 11% of the cases with CNVs, suggesting that
pathogenic position effects are more common in patients
with balanced SVs than in patients with unbalanced SVs
(Fig. 4b). No driver genes were identified for 39% of the
previously considered pathogenic CNVs (based on recur-
rence in other patients). In some cases, the potential
drivers may remain unidentified because of incomplete-
ness of the HPO database or insufficient description of the
patient’s phenotypes. However, given the WGS results de-
scribed for our patient cohort, it is also likely that some
complexities of the CNVs may have been missed by the
array-based detection method. The data also suggests that
many disease-causing genes or mechanisms are still not
known and that some SVs are incorrectly classified as
pathogenic.
Discussion
More than half of the patients with neurodevelopmental
disorders do not receive a diagnosis after regular genetic
testing based on whole-exome sequencing and microarray-
based copy number profiling [3]. Furthermore, the molecu-
lar mechanisms underlying the disease phenotype often
remain unknown, even when a genetic variant is diagnosed
as (potentially) pathogenic in an individual, as this is often
only based on recurrence in patients with a similar pheno-
type. Here, we applied an integrative method based on
WGS, computational phenomatching and prediction of
position effects to improve the diagnosis, and molecular
(See figure on previous page.)
Fig. 3 SVs can affect multiple candidate drivers which jointly contribute to a phenotype. a Number of patients whose phenotype can be partially
or largely explained by the predicted T1/T2 candidate drivers (based on the percentage of the patient’s HPO terms that have a phenomatch
score > 4). These molecular diagnoses are based on the fraction of HPO terms assigned to the patients that have a phenomatch score of more
than 5 with at least one T1/T2 driver gene. b Scatterplot showing the number of predicted T1/T2 candidate drivers compared to the total
number of genes at or adjacent (< 2 Mb) to the de novo SVs per patient. c Heatmap showing the association of the four predicted T1/T2
candidate drivers with the phenotypic features (described by HPO terms) of individual P25. The numbers correspond to the score determined by
phenomatch. The four genes are associated with different parts of the complex phenotype of the patient. d Ideogram of the derivative (der)
chromosomes 6, 12, and 20 in individual P25 reconstructed from the WGS data. WGS detected complex rearrangements with six breakpoint
junctions and two deletions on chr6 and chr20 respectively of ~ 10 Mb and ~ 0.6 Mb. e Circos plot showing the genomic regions and candidate
drivers affected by the complex rearrangements in individual P25. Gene symbols of T1/T2 and T3 candidate drivers are shown respectively in red
and black. The breakpoint junctions are visualized by the lines in the inner region of the plot (red lines and highlights indicate the deletions). The
middle ring shows the log2 fold change RNA expression changes in lymphoblastoid cells derived from the patient compared to controls
measured by RNA sequencing. Genes differentially expressed (p < 0.05) are indicated by red (log2 fold change < − 0.5) and blue (log2 fold change
> 0.5) bars. The inner ring shows the organization of the TADs and their boundaries (indicated by vertical black lines) in germinal zone (GZ) brain
cells [35]. TADs overlapping with the de novo SVs are highlighted in red. f Genomic distance (in base pairs) between the indirectly affected
candidate driver genes and the closest breakpoint junction. Most candidate drivers are located within 1 Mb of a breakpoint junction (median
distance of 185 kb)
Fig. 4 In silico prediction of candidate drivers in larger cohorts of patients with de novo SVs. a Comparison between previous SV classifications
with the strongest candidate driver (located at or adjacent (< 1 Mb) to these SVs) predicted by our approach. Two different patient cohorts, one
containing mostly balanced SVs [21] and one containing copy number variants, were screened for candidate drivers. Our method identified T1/T2
candidate drivers for most SVs previously classified as pathogenic or likely pathogenic. Additionally, the method detected T1/T2 candidate drivers
for some SVs previously classified as VUS, which may lead to a new molecular diagnosis. b Quantification of the predicted effects of the SVs on
proposed T1/T2 candidate driver genes per cohort. Individuals with multiple directly and indirectly affected candidate drivers are grouped in the
category described as “Both.” Indirect position effects of SVs on genes contributing to phenotypes appear to be more common in patients with
balanced SVs compared to patients with copy number variants
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understanding of the disease etiology of individuals with de
novo SVs.
Our WGS approach identified additional complexities
of the de novo SVs previously missed by array-based
analysis in 7 of 18 cases, supporting previous findings
that WGS can have an added value in identifying add-
itional SVs that are not routinely detected by microar-
rays [50, 80, 81]. Our results indicate that duplications
in particular are often more complex than interpreted
by microarrays, which is in line with previous studies
[48, 82]. WGS can therefore be a valuable follow-up
method to improve the diagnosis particularly of pa-
tients with copy number gains classified as VUS. Know-
ing the exact genomic location and orientation of SVs
is important for the identification of possible position
effects.
To systematically dissect and understand the impact of
de novo SVs, we developed a computational tool based
on integration of HiC, RNA-seq, and ChIP-seq datasets
to predict position effects of SVs on the regulation of
gene expression. We combined these predictions with
phenotype association information to identify candidate
driver genes. In 9/39 of the complex cases, we identified
candidate drivers that are directly affected by the break-
point junctions of the SVs. Position effects of SVs have
been shown to cause congenital disorders, but their
significance is still unclear [14]. Our method predicted
position effects on genes associated with the phenotype
in 28% and 11% of all studied cases with balanced and
unbalanced de novo SVs, respectively. Previous studies
estimated that disruptions of TAD boundaries may be
the underlying cause of the phenotypes of ~ 7.3% pa-
tients with balanced rearrangements [21] and of ~ 11.8%
of patients with large rare deletions [18]. Our method
identified a higher contribution of position effects in pa-
tients with balanced rearrangements mainly because our
method included more extensive chromatin conform-
ation datasets and also screened for effects that may ex-
plain smaller portions of the phenotypes. Our method,
although it incorporates most of all published chromatin
conformation datasets on untransformed human cells,
focuses on the disruptions of interactions, which is a
simplification of the complex nature of position effects.
It gives an insight in the potential effects that lead to the
phenotypes and prioritizes candidates that need to be
followed up experimentally, ideally in a developmental
context for proofing causality.
SVs can affect many genes, and multiple “disturbed”
genes may together contribute to the phenotype. Indeed,
in eight, cases we found support for the involvement of
multiple candidate drivers that were affected by one or
more de novo SVs. This supports previous findings that
it can be important to consider multigenic effects to ob-
tain a complete genetic diagnosis [79]. Such multigenic
effects may be especially important for patients with
large and complex SVs affecting many genes. This may
underlie the relatively high amount of multigenic effects
we predicted in our cohort compared to previous,
mainly exome sequencing-based work that found a con-
tribution of multilocus variation in 4.9% of cases [79]. In
many of the studied cases, our method did not detect
candidate drivers. This may be due to insufficient data
or knowledge about the genes and regulatory elements
in the affected locus and/or due to missing disease asso-
ciations in the used databases. Additionally, de novo SVs
are also frequently identified in healthy individuals in
whom they do not have any pathogenic impact [83–85].
Some of the detected SVs of unknown significance may
actually be benign and the disease caused by other gen-
etic or non-genetic factors. The datasets underlying our
computational workflow can be easily updated with
more detailed data when emerging in the future, thereby
enabling routine reanalysis of previously identified SVs.
Moreover, our approach can be extended to study the
consequences of SVs in different disease contexts such
as cancer, where SVs also play a major causal role.
Conclusions
Interpretation of SVs is important for clinical diagnosis
of patients with developmental disorders, but it remains
a challenge because SVs can have many different effects
on multiple genes. We developed an approach to gain a
detailed overview of the genes and regulatory elements
affected by de novo SVs in patients with congenital dis-
ease. We show that WGS, if not available as a first-tier
test, can be useful as a second-tier test to detect variants
that are not detected by exome- and array-based
approaches.
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